Society for Neuro-Oncology Annual Meeting 2022
Phase 2 Study of VAL-083 and Radiotherapy in Newly Diagnosed MGMT-unmethylated GBM
Society for Neuro-Oncology Annual Meeting 2022
Recurrent RELA Fusion-Positive Ependymoma Treated with VAL-083 under Expanded Access: A Case Report
Society for Neuro-Oncology Annual Meeting 2022
VAL-083 in Patients with Recurrent Glioblastoma Treated under Expanded Access Program
American Association for Cancer Research Annual Meeting
Dianhydrogalactitol (VAL-083) for the Treatment of Glioblastoma Multiforme (GBM): Impact of Glucose Transporters for Crossing the Blood Brain Barrier (BBB)
Society for Neuro-Oncology Annual Meeting 2021
Phase 2 clinical trial of dianhydrogalactitol (VAL-083) in patients with newly diagnosed MGMT-unmethylated GBM
Society for Neuro-Oncology Annual Meeting 2021
Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT unmethylated, bevacizumab naïve glioblastoma in the adjuvant or recurrent setting
American Association for Cancer Research Annual Meeting
Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the adjuvant or recurrent setting
American Association for Cancer Research Annual Meeting
Phase 2 study of dianhydrogalactitol (VAL-083) in patients with newly-diagnosed, MGMT-unmethylated glioblastoma
